Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine

BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine in adults. The efficacy and safety of fremanezumab for migraine prevention have been demonstrated in ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Driessen, Maurice T., Cohen, Joshua M., Thompson, Stephen F., Patterson-Lomba, Oscar, Seminerio, Michael J., Carr, Karen, Totev, Todor I., Sun, Rochelle, Yim, Erica, Mu, Fan, Ayyagari, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109352/
https://www.ncbi.nlm.nih.gov/pubmed/35578182
http://dx.doi.org/10.1186/s10194-022-01415-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109352/
https://www.ncbi.nlm.nih.gov/pubmed/35578182
http://dx.doi.org/10.1186/s10194-022-01415-x

Ejemplares similares